Drug Topics
DECEMBER 1, 2022
Although it’s safe and recommended to co-administer these shots, research finds a reduction in flu vaccine uptake the following year.
IDStewardship
DECEMBER 1, 2022
In this article a pharmacist with advanced training and experience in infectious diseases discusses five things pharmacists should know about ventilator associated pneumonia (VAP). Authored By: Lucia Rose, PharmD, BCIDP. Article Posted 1 December 2022. It was the fall of 2009; I was a proud PGY-1 resident at UMass Medical Center rounding with a large team in the ICU.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
DECEMBER 1, 2022
Lecanemab is an investigational anti-amyloid beta antibody to treat mild cognitive impairment due to Alzheimer’s disease. It is currently under review by the FDA and a decision is expected by January 6, 2023.
PhRMA
DECEMBER 1, 2022
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the biopharmaceutical ecosystem are its researchers. Each day, in labs across the country, these individuals work tirelessly on the front lines of research and development to help bring novel medicines to patients.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaVoice
DECEMBER 1, 2022
Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.
Drug Topics
DECEMBER 1, 2022
The treatment is approved for preventing recurrent Clostridioides difficile infections.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
DECEMBER 1, 2022
A look at what’s to come in the December issue of Drug Topics®.
Pharmacy Times
DECEMBER 1, 2022
DeepTCR system showed efficacy as a predictive clinical tool and provided information on the biological mechanisms that underlie how patients respond to immunotherapy.
Fierce Healthcare
DECEMBER 1, 2022
Rough investments, rising costs push Cleveland Clinic's 9-month losses past $1.5B. dmuoio. Thu, 12/01/2022 - 15:00.
Pharmacy Times
DECEMBER 1, 2022
Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
DECEMBER 1, 2022
UnitedHealth, American Nurses Foundation team on pilot to tackle nurse burnout. pminemyer. Thu, 12/01/2022 - 16:56.
Pharmacy Times
DECEMBER 1, 2022
Individuals who had COVID-19 were 55% more likely to develop epilepsy or seizures over the following 6 months than those who had influenza.
Fierce Healthcare
DECEMBER 1, 2022
As major hospitals now bill for some patient-provider messaging, the move could usher wider adoption. dmuoio. Thu, 12/01/2022 - 17:48.
Pharmacy Times
DECEMBER 1, 2022
Data suggest that few US adults are aware that wine can increase the risk of cancer.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
DECEMBER 1, 2022
Florida panel hands TeamHealth a win in its ongoing battle with UnitedHealthcare. pminemyer. Thu, 12/01/2022 - 15:34.
Pharmacy Times
DECEMBER 1, 2022
Commonly known as “relationship addiction,” co-dependency involves emotional, spiritual, physical, or mental enmeshment with a loved one.
Fierce Healthcare
DECEMBER 1, 2022
Senators to Medicare Advantage plans: Get your provider directories in order. rking. Thu, 12/01/2022 - 16:41.
Pharmacy Times
DECEMBER 1, 2022
The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Store News
DECEMBER 1, 2022
IoT sensing tools offer a simplified solution to regulatory compliance complexities.
Pharmacy Times
DECEMBER 1, 2022
Patient selection is a key factor in the safe and effective administration of advanced pain management modalities.
Fierce Healthcare
DECEMBER 1, 2022
Is Digital Health Closing Gaps in Health Equity? ncapone. Thu, 12/01/2022 - 12:54.
Pharmacy Times
DECEMBER 1, 2022
Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.
Fierce Pharma
DECEMBER 1, 2022
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2. kdunleavy. Thu, 12/01/2022 - 10:14.
STAT
DECEMBER 1, 2022
Gilead Sciences won a key round in its battle with the U.S. government over allegations that the Centers for Disease Control and Prevention breached several contracts and “secretly” obtained patents stemming from research that led to the groundbreaking Truvada pill for preventing HIV. As part of a broader fight with the agency over research and resulting patent rights to the medication, the company had filed a lawsuit in 2020 alleging the CDC violated the terms of a 15-year-old col
Fierce Pharma
DECEMBER 1, 2022
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug. aliu. Thu, 12/01/2022 - 15:03.
Drug Store News
DECEMBER 1, 2022
BJ’s Media Edge, which utilizes Microsoft PromoteIQ, looks to offer brands a comprehensive advertising solution to connect with shoppers.
Fierce Pharma
DECEMBER 1, 2022
PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex. ntaylor. Thu, 12/01/2022 - 11:05.
Pharmaceutical Technology
DECEMBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above. A live biotherapeutic, Rebyota is intended for usage following the completion of antibiotic treatment. Rebyota’s safety and efficacy were analysed in the largest trial programme in the microbiome-based therapeutics field, including five trials enrolling over 1,000 subjects.
Fierce Pharma
DECEMBER 1, 2022
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial. ntaylor. Thu, 12/01/2022 - 09:45.
STAT
DECEMBER 1, 2022
Amgen released detailed data on Thursday suggesting an early-stage drug can induce significant weight loss in patients with obesity, with less frequent dosing than current treatments but a safety profile that remains unclear. The results for the molecule, codenamed AMG133, throw Amgen in a long-gestating race with other major drugmakers that burst into the popular press this year.
Fierce Healthcare
DECEMBER 1, 2022
Texas docs file latest legal challenge to surprise billing rule, arguing arbitration process unfair. rking. Thu, 12/01/2022 - 14:43.
STAT
DECEMBER 1, 2022
A recent essay in Health Affairs, a prominent health care journal, proposed a useful-sounding idea: The government should create a new federal designation for “essential hospitals” — hospitals that, according to their own metrics, serve a safety-net role but aren’t currently recognized as such. But it isn’t useful at all.
European Pharmaceutical Review
DECEMBER 1, 2022
Results from a Phase II/III study , published in The Lancet , showed a single, oral dose of acoziborole was up to 95 percent successful in treating sleeping sickness (human African trypanosomiasis). About the Phase II/III study. Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. 208 patients were recruited at 10 hospitals in the Democratic Republic of the Congo (DRC) and
Expert insights. Personalized for you.
469 
Let's personalize your content